Results

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.

Enrolment

Eingeschlossene Patienten: 20.147 (Stand 1. Januar 2021) 
Amgevita® (Adalimumab)103
Benepali® (Etanercept)760
Cimzia® (Certolizumab)943
Enbrel® (Etanercept)2865
Erelzi® (Etanercept)320
Flixabi® (Infliximab)8
Hulio® (Adalimumab)62
Humira® (Adalimumab)2903
Hyrimoz® (Adalimumab)79
Idacio® (Adalimumab)16
Imraldi® (Adalimumab)101
Inflectra™ (Infliximab)16
Kevzara® (Sarilumab)146
Kineret® (Anakinra)89
MabThera® (Rituximab)1458
Nepexto® (Etanercept)6
Olumiant® (Baricitinib)423
Orencia® (Abatacept)857
Remicade® (Infliximab)762
Remsima® (Infliximab)11
Rinvoq® (Upadacitinib)111
Rixathon® (Rituximab)14
RoActemra® (Tocilizumab)1330
Simponi® (Golimumab)446
Xeljanz® (Tofacitinib)331
Zessly® (Infliximab)2
Kontrollen5985

Update: August 1st, 2018; enrolled patients: 17,522

Benepali® (Etanercept)   447
Cimzia® (Certolizumab)   841
Enbrel® (Etanercept) 2859
Erelzi® (Etanercept)     65
Flixabi® (Infliximab)       1
Humira® (Adalimumab) 2883
Inflectra® (Infliximab)     16
Kevzara® (Sarilumab)     20
Kineret® (Anakinra)     89
MabThera® (Rituximab)  1459
Olumiant® (Baricitinib)    167
Orencia® (Abatacept)    718
Remicade® (Infliximab)    762
Remsima® (Infliximab)       9
RoActemra® (Tocilizumab)  1260
Simponi® (Golimumab)    428
Xeljanz® (Tofacitinib)    106
Control Group  5392